A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

July 4, 2023

Study Completion Date

July 4, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

A:YH002+YH001

YH002 on CnD1,YH001 on CnD8,Q3W

DRUG

B:YH002+YH001

YH002 and YH001 on same day,Q3W

DRUG

YH002+YH001

A traditional 3+3 dose escalation algorithm

Trial Locations (9)

2109

Macquarie University Hospital, Sydney

2800

Orange Health Services, Orange

3144

Cabrini Hospital Malvern, Malvern

3199

Peninsula and South Eastern Haematology & Oncology Group, Frankston

110801

Liaoning Cancer Hospital, Shenyang

200020

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

310020

Sir Run Run Shaw Hospital, Hangzhou

430022

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450008

Henan Tumor Hospital, Zhengzhou

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY